Found 97 Vision Loss trials
A listing of Vision Loss medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
This is a double-blind, placebo controlled study to assess the safety and efficacy of BI1015550 on patients with IPF. It is a phase 3 study and will including physical exams, a CT, questionnaires, safety lab samples, lung function testing, and ECGs.
A5394 is a phase II, randomized, double-blind, placebo-controlled clinical trial to assess the safety, tolerability, and efficacy of 24 weeks of treatment with Selgantolimod (SLGN). Intensive PK sampling will be conducted in the first 12 participants who enroll into the study.
This is a multicenter, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of CSL112 on reducing the risk of major adverse CV events (MACE) in subjects with Acute Coronary Syndrome (diagnosed with STEMI or NSTEMI), who are receiving evidence-based medical therapy.
This is a prospective, multi-center, double-blind, randomized, placebo-controlled, parallel-group, exploratory Phase 4 study. The purpose is to identify the effect of selexipag on daily life physical activity assessed by a wearable device in patients with PAH (WHO Group 1). Approximately 100 patients will be enrolled in the study at 45 …
Parallel, Randomized, Double-Blind, Placebo-Controlled Crossover Clinical Trial The primary objective is to evaluate the safety of oral LT3 in heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF) The secondary objective is to evaluate the feasibility and preliminary efficacy outcomes of oral LT3 therapy …
Please see Section 1 of the attached protocol.
PROOF-HD is a placebo-controlled (double blind) multicenter Phase 3 trial of Pridopidine in Huntington Disease patients. Recruitment: 480 participants at 60 sites, a target of 8 participants per site. Procedures include administration of study drug or placebo in tablet form twice daily for a period of 67-80 weeks with option …
Efficacy of nipocalimab in patients with warm autoimmune hemolytic anemia (wAIHA) Durable response in improvement in hemoglobin (Hgb), defined as attainment of the following at 3 consecutive visits, where at least the first is at or before Week 16, without the need of rescue therapy: 1- Hgb concentration greater than …
This protocol is an 18-month, multicenter, randomized, double-blind, placebo-controlled, phase 2 study comparing 1400 mg of donanemab versus placebo over 76 weeks in approximately 500 patients with early symptomatic AD. Study duration including screening and post treatment is up to 133 weeks. Study drug will be prepared and stored at …
This is a 52 wk, randomized, double-blind study to demonstarte the clinical efficacy, safety, and tolerability of ianalumab compared to placebo in patients with active Sjogren's syndrome. Pts will receive a subcutaneous injection of ianalumab/placebo monthly, in addition to salivary flow assessments, blood and urine sampling, PROs, and optional assessments …
Please choose between Voice or SMS based delivery of verification code
or